诺诚健华2026年临床研发与商业化关键节点梳理

Core Insights - The company, Nocera Biopharma-U (688428), is making significant progress in clinical research, partnerships, and product commercialization in 2026. Clinical Development Progress - ICP-488 (highly selective TYK2 inhibitor) has completed patient enrollment for its Phase III clinical trial for psoriasis, with a total of 383 patients enrolled, marking a key clinical milestone [2] - Soficitinib (TYK2 inhibitor) has completed patient enrollment for its Phase III registration trial for moderate to severe atopic dermatitis, with accelerated trials for indications like vitiligo and nodular prurigo [2] - Obinutuzumab (BTK inhibitor) has completed its Phase III clinical study for idiopathic thrombocytopenic purpura (ITP) and is expected to submit a New Drug Application (NDA) in the first half of 2026; a Phase IIb study for systemic lupus erythematosus (SLE) has met its primary endpoint, with a Phase III trial set to begin soon [3] - BCL2 inhibitor (Mesutoclax/ICP-248) is advancing two registration Phase III clinical studies in the hematological malignancies field [3] Collaboration and International Expansion - The partnership with Zenas BioPharma, established in October 2025, plans to initiate a global Phase III clinical trial for Obinutuzumab targeting secondary progressive multiple sclerosis (SPMS) in the first quarter of 2026; Zenas will also advance two preclinical molecules from Nocera Biopharma into clinical stages in 2026. The total potential value of this collaboration exceeds $2 billion, including milestone payments and royalties [4] Commercialization and Product Pipeline - Newly approved drugs, Tansimod (Mingnuokai) and Zolbetuximab (Yinuoxin), which were approved in 2025, are now on the market and expected to contribute to revenue growth alongside Obinutuzumab. The new indications for Obinutuzumab (such as first-line treatment for CLL/SLL) are anticipated to drive continued sales growth [5] - The company achieved profitability for the first time in 2025, with revenue of approximately 2.37 billion yuan and a net profit of about 630 million yuan. Management indicates that the company will enter a phase of sustainable profitability starting in 2025, focusing on global expansion and pipeline diversification to solidify performance [5]